Add to ORKGThe potential of targeted therapy with radiolabeled peptides has been reported in several clinical trials. Although there have been many improvements in dose estimation, a general and reliable dosimetric approach in peptide receptor radionuclide therapy (PRRT) is still amatter of debate. This article reviews themethods for PRRT dosimetry and the results presented in the literature. Radiopharmaceutical characteristics, data processing, dosi-metric outcomes, and methods to protect critical organs are reported. The biological effective dose, based on the linear qua-dratic model, is also described. Key Words: dosimetry; peptide receptor radionuclide therapy
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metasta...
Radiolabeled peptides have become important tools for preclinical cancer research, and in nuclear on...
Peptide receptor radionuclide therapy (PRRT) has been constantly evolving over the last decade, prov...
Abstract Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SR...
Peptide Receptor Radionuclide Therapy (PRRT) has proven its efficacy in the treatment of neuroendocr...
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting rad...
The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparin...
The development of dosimetry and studies in peptide receptor radionuclide therapy (PRRT) over the pa...
PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pr...
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effect...
A series of radiolabeled peptides have been designed and optimized for tumor-targeted peptide recept...
Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of neuroendocri...
Item does not contain fulltextDuring the past decade, radiolabeled receptor-binding peptides have em...
textabstractPeptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metasta...
Radiolabeled peptides have become important tools for preclinical cancer research, and in nuclear on...
Peptide receptor radionuclide therapy (PRRT) has been constantly evolving over the last decade, prov...
Abstract Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SR...
Peptide Receptor Radionuclide Therapy (PRRT) has proven its efficacy in the treatment of neuroendocr...
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting rad...
The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparin...
The development of dosimetry and studies in peptide receptor radionuclide therapy (PRRT) over the pa...
PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pr...
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effect...
A series of radiolabeled peptides have been designed and optimized for tumor-targeted peptide recept...
Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of neuroendocri...
Item does not contain fulltextDuring the past decade, radiolabeled receptor-binding peptides have em...
textabstractPeptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metasta...
Radiolabeled peptides have become important tools for preclinical cancer research, and in nuclear on...